SCHEMBL7236541

SCHEMBL7236541

Clc1nccc(N2Cc3ccccc3C2)n1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 10/20 0.44
GRIN2D O15399 5/20 0.44
GRIN3B O60391 5/20 0.44
GRIN1 Q05586 5/20 0.44
GRIN2A Q12879 5/20 0.44
GRIN2B Q13224 5/20 0.44
GRIN2C Q14957 5/20 0.44
GRIN3A Q8TCU5 5/20 0.44
RPS6KA5 O75582 1/20 0.43
EGFR P00533 2/20 0.42
CHRM1 P11229 1/20 0.42
ADRA1D P25100 1/20 0.42
ADRA1A P35348 1/20 0.42
ADRA1B P35368 1/20 0.42
SORD Q00796 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13028399 0.78 TRPV1 (0.47) TRPV1ADRA1DADRA1AADRA1B
SCHEMBL16637778 0.78 ROCK2 (0.53) TRPV1
SCHEMBL27805031 0.76 SORD (0.66) TRPV1SORD
SCHEMBL1427479 0.76 TRPV1 (0.51) TRPV1SORD
SCHEMBL29519276 0.76 TRPV1 (0.51) TRPV1SORD
SCHEMBL3949154 0.76 TRPV1 (0.51) TRPV1SORD
SCHEMBL29997962 0.75 HRH4 (0.65) TRPV1SORD
SCHEMBL2190955 0.75 HRH4 (0.65) TRPV1SORD
SCHEMBL19965019 0.74 RPS6KA5 (0.38) TRPV1RPS6KA5SORD
SCHEMBL28477218 0.74 RPS6KA5 (0.38) TRPV1RPS6KA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183231-A1 MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS Valo Health, LLC 2023-06-15 US disclosed
US-20230183231-A1 MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS Valo Health, LLC 2023-06-15 US disclosed
US-11548886-B2 Monocyclic compounds useful as GPR120 modulators VALO HEALTH, INC. (US) 2023-01-10 US disclosed
US-20210101896-A1 MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS Valo Health, LLC 2021-04-08 US disclosed
US-10800773-B2 Monocyclic compounds useful as GPR120 modulators INTEGRAL HEALTH, INC. (US) 2020-10-13 US disclosed
US-20190202821-A1 MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS Valo Health, LLC 2019-07-04 US disclosed
WO-2018049324-A1 MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS NUMERATE, INC. (US) 2018-03-15 WO disclosed
US-20030055263-A1 Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11548886-B2 Monocyclic compounds useful as GPR120 modulators GPR119, GPR180, GPR65 TRPV1 142/4885GRIN2D 762/4885GRIN3B 315/4885
US-10800773-B2 Monocyclic compounds useful as GPR120 modulators GPR119, GPR180, GPR65 TRPV1 142/4885GRIN2D 762/4885GRIN3B 315/4885
US-20210101896-A1 MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS GPR119, GPR180, GPR65 TRPV1 142/4885GRIN2D 762/4885GRIN3B 315/4885
US-20190202821-A1 MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS GPR119, GPR180, GPR65 TRPV1 142/4885GRIN2D 762/4885GRIN3B 315/4885
US-20030055263-A1 Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production TERT, POT1, REV1 TRPV1 2572/4885GRIN2D 3586/4885GRIN3B 3701/4885
US-20230183231-A1 MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS GPR119, GPR180, GPR65 TRPV1 142/4885GRIN2D 762/4885GRIN3B 315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.